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ABSTRACT: Through the recently developed copper-mediated photo-induced living radical polymerization (CP-LRP), a novel 
and well-defined polymeric prodrug of the antimicrobial lipopeptide colistin has been developed. A colistin initiator (Boc5-col-Br2) 
was synthesized through the modification of colistin on both of its threonine residues using a cleavable initiator linker, 2-(2-bromo-
2-methylpropanoyloxy) acetic acid (BMPAA) and used for the polymerization of acrylates via CP-LRP. Polymerization proceeds 
from both sites of the colistin initiator, and through the polymerization of PEGA480, three water-soluble polymer-colistin conjugates 
(col-PPEGA, DP = 5, 10, 20) were achieved with high yield (conv. ≥ 93%) and narrow dispersities (Đ < 1.3) in 2 – 4 hours. Little 
or no effect on the structure/activity of the colistin was observed during the synthesis and most of the active colistin can be recov-
ered from the conjugates in vitro within 2 days. Furthermore, in vitro biological analyses including disk diffusion, broth microdilu-
tion and time-kill studies suggested all the conjugates have the ability to inhibit the growth of multi-drug resistant (MDR) Gram-
negative bacteria, of which col-PPEGA DP5 and DP10 showed similar or better antibacterial performance compared to the clinical-
ly relevant colistin prodrug CMS, indicating their potential as an alternative antimicrobial therapy. Moreover, considering the con-
trol over the polymerization, CP-LRP technique has the potential to provide an alternative platform for the development of polymer 
bioconjugates. 
INTRODUCTION 
The development of new antimicrobial agents against bacte-
rial infections is difficult and time/cost consuming.1-4 With the 
increasing amount of drug-resistant infections and the emer-
gence of multi-drug resistant (MDR) Gram-negative bacteria, 
aka ’superbugs’, a lack of effective drugs and treatments is 
threatening humans all over the world and might have severe 
consequences if no action is taken.5,6 Antibiotic resistance 
currently accounts for an estimated 50,000 deaths in the US 
and Europe, with estimates that the actual current death toll is 
ca. 700,000 worldwide. If antibiotic resistance were allowed to 
grow unabated the number of deaths per year would dramati-
cally increase to an estimated 10 million by 2050.7 To combat 
these ‘superbugs’, colistin, an antibiotic from the polymyxin 
family has recently re-attracted the attention of researchers.8-11 
As one of the most potent peptide-based antimicrobial agents 
against MDR Gram-negative bacteria, colistin is a double-
edged sword in clinical treatments due to its potential toxicity 
to human kidneys and the nervous system at high dose and 
sometimes required long treatment regimens.12-15 To date, sev-
eral approaches have been developed for localized infection 
treatments, including inhaled colistin for lung infections16 or 
colistin patches for wound infections.17 However due to their 
intrinsic toxicity, intravenous applications have remained chal-
lenging.  
The only FDA-approved colistin formulations available for 
systematic administration is the prodrug colistin methanesul-
fonate (CMS).18  Modified on the five colistin amines, this 
inactive prodrug is a less toxic compound that can be convert-
ed to active colistin in vivo.18,19 However it is widely acknowl-
edged that the clinical application of CMS still suffers from a 
number of important drawbacks. For example, its pharmaco-
kinetic properties are far from ideal due to the slow release 
rate, approximately 60% of the dosed CMS is excreted in the 
urine in the first 24 hours administration before being hydro-
lyzed to active colistin.20 Also importantly, as there are 5 
amines capable of undergoing modification during the prepa-
ration of CMS, there are potentially 32 (= 25) chemical varia-
tions, including unmodified colistin, that can be present in 
CMS formulations, leading to both structural and therefore 
dose variation from batch to batch, which can have a signifi-
cant negative impact on clinical outcomes.19,21  
In an effort to find a replacement for CMS, a more structur-
ally controlled polymeric colistin prodrug (col-aaPEG) has 
been previously developed.22 In contrast to the amine modifi-
 cation in CMS, an acetic acid terminal poly(ethylene glycol) 
methyl ether (aaPEG) was attached onto colistin threonine 
(Thr) residues to minimize the diversity of the modification 
site and to increase its bioavailability and improve its pharma-
cokinetics/pharmacodynamics performance. This hydrolyzable 
PEGylated colistin showed an encouraging in vitro and in vivo 
performance similar to CMS and revealed no systematic tox-
icity or nephrotoxicity. However, there remain two potential 
modification sites for the more active col-aaPEG monoconju-
gate and it is not easy to control selectivity between the two 
Thr residues. Conversely, col-aaPEG2 with well-defined modi-
fication at both Thr residues showed a slower release rate and 
lower activity compared to its monoconjugate analogue. Thus, 
a colistin prodrug with well-defined site modification, i.e. 
modification at both Thr residues, with a suitable colistin re-
lease profile may be of significant advantage. 
As an alternative to our previous ‘grafting-to’ strategy for 
colistin modification, the ‘grafting-from’ approach to pro-
tein/peptide modification confers a number of advantages. The 
addition of functional small molecules, unhindered by bulky 
polymer chains, facilitates complete and specific modification 
of the residues of interest on the target protein/peptide.23,24 
Typically, using this approach moieties capable of mediating 
polymerization such as α-halo ester/amide initiators or thio-
carbonylthio chain transfer agents are initially conjugated to 
proteins/peptides. The resulting modified structures can be 
fully and precisely characterized by conventional methods 
before being employed in polymerizations to afford polymer 
conjugates. Furthermore, the purification of the resulting con-
jugates is much less intensive than for ‘grafting-to’ techniques, 
as relatively large conjugates are easily separated from small 
molecule impurities, which include unreacted monomer and 
other necessary reagents in solution. 
Recent developments in reversible-deactivation radical 
polymerizations (RDRP), such as reversible addi-
tion−fragmentation chain transfer polymerization (RAFT)25,26 
and Cu-mediated polymerizations; atom transfer radical 
polymerization (ATRP),23,27 and single-electron transfer living 
radical polymerization (SET-LRP),28,29 bestow excellent con-
trol over the molecular weight and dispersity (Đ) of polymers 
maintaining high end-group fidelity. The use of external stim-
uli (i.e., pressure, electricity and light) enables polymeriza-
tions to be performed under relatively mild reaction condi-
tions, even mimicking physiological environments, whilst 
maintaining and even accelerating the rate of reaction and 
retaining control over the polymerization.30-32  
One such technique, Cu-mediated photo-induced polymeri-
zation (CP-LRP),33,34 has been studied using visible/UV light, 
employing a CuII(Me6-Tren)Br2 complex in the presence of an 
excess of tris[2-(dimethylamino)ethyl]amine (Me6Tren), al-
lows polymerization to take place at and below ambient tem-
perature with near perfect temporal control over the molecular 
weight, dispersity and chain-end fidelity at relatively low cata-
lyst loadings (2 mol% w.r.t. initiator) in the absence of con-
ventional photoinitiators or dye-sensitizers. To date there have 
been no reports of this novel technique being employed for the 
preparation of protein/peptide-polymer conjugates via either 
the ‘grafting-to’ or ‘grafting-from’ methods. The versatility of 
the approach and its demonstrated use in the polymerization of 
a wide range of monomer types expands the potential polymer 
compositions that can be attached to peptides/proteins through 
the simple variation of the (co)monomer feed, which im-
portantly includes easy access to poly[poly(ethylene glycol) 
methyl ether (meth)acrylate] (PPEG(M)A) grafted materials 
which are well established as an alternative to linear PEG.23, 24 
Synthetic issues associated with the attachment of linear PEG 
to colistin are exacerbated by increasing molecular weight.35 
Similarly, the viscosity and crystallinity of linear PEG in-
creases with molecular weight, as does the propensity for or-
gan accumulation and vacuolization, making it less suitable 
for intravenous administration.36-38 The comb-like architecture 
of PPEG(M)A materials, with their PEG side chains impart a 
rigid rod-like structure in aqueous solution, which reduces the 
viscosity compared to linear PEG of the same molecular 
weight.38 More importantly, due to its non-crystalline proper-
ties, PPEG(M)A does not demonstrate the accumulation in, or 
damage of, human tissues that has been attributed to linear 
PEG.36 
To address these problems, we have investigated the use of 
CP-LRP to prepare well-defined peptide-polymer conjugates 
using a ‘grafting-from’ approach for the first time. To achieve 
both site specificity and efficient release of colistin we have 
used a new hydrolytically labile α-halo ester initiating group to 
modify the two Thr residues. The linker has been specifically 
selected to provide an enhanced release rate relative to the 
acetic acid linker (aaPEG), which has been used previously. 
Conjugates have been prepared with good control of the graft-
ed polymer molecular weight and narrow dispersities, as con-
firmed by full characterization of the polymers released from 
the conjugates. The effect of the degree of polymerization on 
the colistin release rate and bioactivity has been thoroughly 
evaluated by in vitro disk diffusion, broth dilution and time-
kill assays.  We demonstrate that, subject to efficient release, 
the polymeric colistin prodrugs have little or no observable 
effect on the structure or antimicrobial activity of the colistin. 
Scheme 1 Acid dissociation constant at logarithmic scale of 
the acids with different side groups and their relative initi-
ator linker.  
 
RESULTS AND DISCUSSIONS 
Design of the Initiator Linker for Colistin Conjugation. 
The colistin release rate from the polymeric prodrug would 
greatly affect the final antimicrobial activity and this phenom-
ena would be more significant on the double modified colistin 
conjugate due to a two-step hydrolysis profile.22 Thus the de-
sign of the linker between colistin and the initiating group is 
important to the proposed ‘grafting from’ approach for the 
formation of a suitable prodrug candidate. In order to obtain 
an improved performance and a faster colistin release rate, a 
labile linker comparable to that present in the linear aaPEG is 
a required design prerequisite in order to afford a suitable hy-
drolysis whilst counteracting the two-step hydrolysis effect.22  
 The stability of an ester is influenced by the neighboring 
groups of the carboxyl group. A more acidic group (quantified 
by the acid dissociation constant Ka) which normally has a 
stronger electron withdrawing effect, can act as a better leav-
ing group, leading to a faster ester hydrolysis rate. Due to the 
same reason, the linear PEG-conjugate col-saPEG hydrolyzed 
slower than col-aaPEG.22 Thus, based on pKa values, 2-(2-
bromo-2-methylpropanoyloxy)acetic acid (BMPAA) was syn-
thesized and chosen as the initiator linker (Scheme 1). 
Prior to the attachment of this initiator linker to colistin, all 
colistin amine residues were protected by tert-
butyloxycarbonyl (Boc) groups (Boc5-col).
22 The initiator 
linker was subsequently attached onto both colistin Thr resi-
dues using Steglich esterification (Figure 1a). As the commer-
cial colistin contains two major components (colistin A and B), 
both colistin peaks with a clear molecular weight increase 
(414 Da) were observed from the modified product (Boc5-col-
Br2) compared to Boc5-col through matrix-assisted laser de-
sorption/ionization-time of flight mass spectrometry (MALDI-
ToF MS), indicative of the attachment of two initiator groups 
(Figure 1b). The isotope pattern of Boc5-col-Br2 also suggested 
that this compound contains two bromine atoms (Figure 1c), 
further confirming the successful attachment of two initiators 
on Boc5-colistin and the stability of both bromines of the initi-
ators under the reaction conditions. 
 
 
Figure 1 a) The Boc-protection reaction on colistin Dab amines and the subsequent modification of the labile BMPAA initiator on colistin 
Thr groups, b) MALDI-ToF MS data of native colistin (black), Boc5-col (red), and Boc5-col-Br2 (blue) and c) The zoom-in data of Boc5-
col-Br2. 
 
 Figure 2 a) Scheme of the polymerization of MA using the colistin initiator via CP-LRP and the further cleavage of PMA colistin conju-
gate using NaOMe (3% in MeOH), b) GPC and c) MALDI-ToF MS of the Boc5-col-PMA conjugate before (black traces) and after (red 
traces) treating with NaOMe.
Polymerization of PEGA480 from the Colistin Initiator. 
Due to both the hydrolytic and heat sensitive features of both 
colistin and the labile initiator linker, compatible polymeriza-
tion conditions, such as low temperature and a non-aqueous 
solvent were required. Thus, CP-LRP was explored to achieve 
polymerization from the colistin initiator.33 Although this 
technique has shown to be a versatile and robust platform, to 
the best of our knowledge, a peptide-based initiator has not yet 
been investigated. Moreover, it was not certain whether the 
UV light would have an undesirable effect on the peptide un-
der these conditions. Firstly, methyl acrylate (MA) was used 
as a model monomer to study the feasibility of the polymeriza-
tion (Figure 2a). 
The total degree of polymerization (DP) was set to 40 (20 
for each initiating site) to achieve a better resolution from both 
nuclear magnetic resonance (NMR) and MALDI-ToF MS 
analyses. The reaction was carried out under UV light (λmax ~ 
360 nm) with copper(II) bromide (CuBr2) and Me6Tren as the  
ligand at a ratio of 0.02:0.12:1 relative to the colistin initiator. 
Anhydrous DMSO was used so as to prevent initiator hydroly-
sis during the polymerization. A cooling plate was also applied 
to maintain the reaction temperature (~ 15 oC), further lower-
ing the propensity of any side reactions. The conversion of 
MA was measured through NMR analysis of the reaction mix-
ture, comparing the vinyl groups (δ = 5.70 - 6.35 ppm, Figure 
S1b, peak b-d) against the signal of methyl group on both the 
unreacted monomer and the formed polymer (δ = 3.48 -3.68 
ppm, Figure S1b, peak a and a’). This revealed that around 
96% of the methyl acrylate was converted into polymer after 4 
h polymerization. A monomodal peak with narrow dispersity 
(Đ ~ 1.12) was observed through gel permeation chromatog-
raphy (GPC) analysis (Figure 2b, black trace), suggesting that 
the MA monomer polymerized successfully from the colistin 
initiator and that the polymerization was controlled. This also 
indicated that the colistin peptide structure did not disrupt the 
polymerization process. 
As there are two initiating sites in the colistin initiator, a fur-
ther cleavage experiment was performed on the PMA colistin 
conjugate (Boc5-col-PMA) under basic conditions (3 wt% 
sodium methoxide, NaOMe) in order to investigate whether 
the polymerization had occurred from both sites (Figure 2a). 
The cleaved product was found to be monomodal with approx-
imately half the molecular weight of the initial polymer col-
istin conjugate through both GPC and MALDI-ToF MS anal-
yses (Figure 2b-c), confirming that well-defined polymer 
chains were grown in a controlled way at both initiator sites in 
the colistin. Moreover, the peaks belonging to Boc5-col were 
also observed via MALDI-ToF MS after the cleavage of the 
PMA chains (Figure 2c, red trace), indicating that the colistin 
structure was not affected under the polymerization conditions 
chosen. 
Based on these positive results from the MA polymeriza-
tion, PEGA480 was polymerized at three different DPs (DP = 5, 
10 and 20 per initiating site) under similar conditions (Figure 
3). As expected, most of the PEGA480 was consumed after 2-4 
h (monomer conversion ≥ 93%, Table 1) and all the final 
products retained narrow dispersities (Đ ~ 1.1-1.2, Figure 3b-d 
and Table 1), suggesting the successful synthesis of all the 
polymers in a controlled manner. 
 
Figure 3 a) Polymerization of PEGA480 using CP-LRP and the cleavage of the Boc groups on the polymer, b)-d) the GPC traces of the col-
PPEGA conjugates with DP = 5 (b), 10 (c), and 20 (d) in reaction mixture, after purification and after cleavage and e) the HPLC traces of 
the col-PPEGA conjugates before and after the Boc groups cleavage. 
Table 1 Summary of the conversion, molecular weight and dispersities (Đ) of each conjugate analyzed from 1H-NMR and 
GPC. 
DP Conversion (%) MnTheory  (g·mol-1) MnNMR (g·mol-1) MnGPC (g·mol-1) Đ 
5 99 6875 6800 6100 1.13 
10 93 11675 11000 8700 1.20 
20 93 21275 19900 14400 1.21 
  
 
Figure 4 a) Scheme of the hydrolysis process of the col-PPEGA conjugates, b) Degradation of col-PPEGA conjugates (DP = 5) at 37 oC in 
PBS (1X) monitoring by HPLC and c) Different colistin release profiles obtained from col-PPEGA conjugates with different DPs at 37 oC 
or ambient temperature. 
Table 2 The diameter of zone of inhibition (ZOI) results of the colistin-PPEGA conjugates against two different Gram-
negative bacteria through disk diffusion assay (24 h). 
 
Diameter of Zone of Inhibition (ZOI) (cm) 
saline colistin CMS col-PPEGA DP5 col-PPEGA DP10 col-PPEGA DP20 
Pa ATCC 27853 0 1.8 1.7 1 0.8 0 
Ab ATCC 19606 0 1.8 1.8 1.1 0.9 0.65 
Table 3 The minimum inhibitory concentration (MIC) of the conjugates against two different Gram-negative bacteria on a 
mass basis. (Data with* was acquired from Ref. 21) 
Minimum inhibitory concentration against Ab ATCC 19606  (MIC) (mg/L) 
colistin  CMS col-aaPEG col-aaPEG2 col-PPEGA DP5 col-PPEGA DP10 col-PPEGA DP20 
1* 16* 8* 32* 16 16-32 16-32 
Subsequently, the polymers were treated with trifluoroacetic 
acid (TFA, 20% in dichloromethane, DCM), to remove all of 
the Boc groups on colistin to realise the amine residues. A 
clear shift to a shorter retention time was observed in all three 
polymers through high performance liquid chromatography 
(HPLC) analysis, suggesting quantitative removal of the Boc 
groups (Figure 3e). Further, GPC analysis revealed similar 
molecular weights and dispersities before and after the TFA 
cleavage process (Figure 3b-d), indicating the successful syn-
thesis of colistin-PPEGA conjugates with three different DPs 
(col-PPEGA DP5, DP10 and DP20) with both ester bonds 
from the initiator linker being stable under the deprotection 
conditions. 
Hydrolysis Test of col-PPEGA Conjugates. After obtain-
ing the pure col-PPEGA conjugates, the hydrolysis of the link-
ers was investigated at both body and ambient temperature 
using the previously established hydrolysis method with phos-
phate-buffered saline (PBS, 1X, pH = 7.4) used to mimic 
physiological conditions (Figure 4).22 The degradation of the 
col-PPEGA conjugates was monitored by HPLC and revealed 
a two-step degradation process for all three conjugates (Figure 
4b). Typically, the intensity of the col-PPEGA conjugate peak, 
which varied from 14 - 16 min depending on the DP of poly-
mers, gradually reduced over time with the concomitant ap-
pearance of two peaks (9.8 - 10.6 min)  of increasing intensity 
which are assigned to colistin A and B (Figure 4b). An inter-
mediate peak, with a retention time approximately 1.5 min 
earlier than that of the conjugate peak, was attributed to the 
mono-cleaved col-PPEGA conjugate. These peaks appeared 
and continued to increase in intensity over the first 6 h after 
which they were observed to decrease as the result of further 
polymer cleavage. The cleaved PPEGA was also observed by 
HPLC but the signal was relatively low owing to the weak 
absorbance of PPEGA at 214 nm. 
The released colistin peaks were then collected and subse-
quently analyzed by MALDI-ToF MS, which revealed that 
colistin was recovered unmodified and the chemical structure 
remained unaltered further confirming the colistin remained 
unchanged during both the polymerization and the TFA cleav-
age process (Figure S2). Moreover, it confirmed that the initia-
tor linkers were cleaved completely from colistin and that the 
hydrolysis occurred at the ester bond to the colistin rather than 
the ester bonds within the BMPAA linker or the PPEGA pol-
ymer. 
In general, the colistin release rates and release profiles of 
each conjugate were similar (Figure 4c), suggesting the hy-
drolysis of the cleavable linker was not hindered greatly by the 
steric constraints imposed by the large comb-like structure of 
the attached polymers. However it should be noted that a 
slightly lower release rate (5-10%) for higher DP and hence 
molecular weight was observed. 
Disk Diffusion Assay for In Vitro Antimicrobial Activity 
Evaluation of the Col-PPEGA Conjugates with Various 
DPs. In order to evaluate the antibiotic activity of each col-
 PPEGA conjugate, two MDR Gram-negative bacteria strains, 
P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606, 
were first tested through disk diffusion assay. As a facile and 
economic standard, disk diffusion assay provide the visualiza-
tion of the relative antimicrobial activity of each compound 
via a bacteria-free zone (zone of inhibition (ZoI)) from the 
bacteria-cultured agar plate. To this end, 20 µg of each conju-
gate were applied onto a blank disc (Ø = 0.6 cm) before being 
placed on a bacterium inoculated agar plate. Colistin and CMS 
were also tested as positive controls and saline as a negative 
control. The potency of each conjugate could be estimated 
through the measurement of the diameter of ZoI (Table 2).  
As PEG itself has been shown to exhibit no antibiotic activi-
ty and the molecular weight of each col-PPEGA conjugate 
(Table S1) is at least 5-10 times larger than colistin and CMS, 
it was expected that they would demonstrate a lower activity 
with the same mass. We found that indeed col-PPEGA DP20 
did not show a significant activity during the test, however, the 
other two col-PPEGA conjugates still showed a clear ZoI, 
indicating the potency of the released colistin from these col-
istin conjugates. Although the ZoIs are smaller than the ones 
obtained from colistin and CMS, the observed antimicrobial 
activity obtained from col-PPEGA DP5 and DP10 suggested 
the cleavable linker can be effectively hydrolyzed under these 
model physiological conditions, and importantly that this 
‘grafting-from’ approach for colistin conjugation did not alter 
the biological activity of the released colistin. 
Quantitative In Vitro Antimicrobial Activity Evaluation 
of the Col-PPEGA Conjugates with Various DPs via Broth 
Microdilution Method. A further examination for the mini-
mum inhibitory concentration (MIC) of each conjugate was 
performed through a broth microdilution method to achieve a 
more accurate quantitative comparison. Although all the ob-
tained polymer colistin conjugates have a narrow dispersity, 
an accurate comparison through the molar basis is not possi-
ble. Thus, the MIC test was conducted on a mass basis. 
All of the col-PPEGA conjugates have shown antibacterial 
activity against Ab ATCC 19606, indicating active colistin can 
be released from these colistin conjugates (Table 3). Particu-
larly, all these conjugates have comparable or better antimi-
crobial activity than the previous reported doubly functional-
ized col-aaPEG2 even though the molecular weight of these 
conjugates are all larger than col-aaPEG2. This suggests that 
the PPEGA polymer with the BMPAA linker released colistin 
faster than aaPEG2 and that the molecular weight of the comb-
like PPEGA did not greatly hinder the linker hydrolysis which 
is in agreement with the colistin release profile from previous 
studies. Furthermore, col-PPEGA DP5 has a similar activity to 
the commercial prodrug CMS although the average molecular 
weight is around five times larger, highlighting its potential as 
a more efficacious alternative to CMS.  
Kinetics of In Vitro Antimicrobial Activity of the Col-
PPEGA Conjugates with Various DPs. To study the effects 
of the colistin release rate and the DP of the polymer em-
ployed in the col-PPEGA conjugates upon their antibacterial 
kinetics, time-kill studies of the conjugates were performed 
against the A. baumannii ATCC 19606 at three different doses 
referenced to their MICs (0.5 x MIC, 1 x MIC, and 4 x MIC, 
referring to mass based MICs of each compound). Note, if a 
range of MICs was obtained e.g. col-PPEGA DP10 (Table 3), 
calculations were based on the higher MIC value. 
All conjugates showed no significant inhibition towards the 
bacteria at the lower doses of 0.5 x MIC or 1 x MIC. When 
applying a higher dose (4 x MIC), both the DP5 (Figure 5a) 
and DP10 (Figure 5b) polymer-colistin conjugates were found 
to have a similar antibacterial performance when compared to 
the commercial prodrug CMS (Figure S4b), causing a signifi-
cant decrease of the amount of live bacteria in the broth. Nota-
bly, it took 3h for DP5 conjugates (MIC 4x) to inhibit the 
growth of bacteria to levels approaching the detection limit, 
while around 6h was needed for either DP10 conjugate or 
CMS, suggesting the colistin release rate from the conjugates 
played an important role for their bacteria inhibition profiles. 
Although the DP20 polymer conjugate (Figure 5c) did not 
produce a similar effect found from the DP5 and DP10 conju-
gates, an inhibition of bacteria growth was still observed 
through the experiment, suggesting antibacterial activity 
caused by the successful release of colistin.  
 
  
Figure 5 The ‘time-kill’ kinetics with different amount for the col-
PPEGA conjugates with a) DP = 5 , b) DP = 10 and c) DP = 20 
(c). 
CONCLUSION 
In conclusion, we have demonstrated a novel and facile ap-
proach for the synthesis of colisitin polymeric prodrugs with 
enhanced properties. A range of hydrolyzable polymer colistin 
conjugates have been successfully synthesized using a colistin 
initiator, which has been site selectively modified with two 
cleavable initiator precursors (BMPAA) at both Thr residues, 
and a novel ‘grafting-from’ approach via CP-LRP. Through a 
model PMA system, it was confirmed that initiator sites re-
sulted in similar chain growth in a controlled manner and the 
structural integrity of colistin during the polymerization pro-
cess. Site specific colistin-PPEGA conjugates (col-PPEGA) 
with different DPs have been successfully synthesized with 
narrow dispersities (Đ ~ 1.1-1.2) using PEGA480 monomer and 
fully characterized. Moreover, degradation studies under simu-
lated physiological conditions suggested that most of the na-
tive colistin can be recovered from all three conjugates within 
48 hours. The colistin release rate from the three PPEGA con-
jugates were similar though it slightly decreased with increas-
ing DP of the attached polymers. In vitro antimicrobial activity 
tests revealed that all three conjugates remained active against 
the tested MDR Gram-negative bacteria. In particular, col-
PPEGA DP5 and DP10 showed similar or better antibacterial 
activities to CMS. In summary, the combination of state-of-
the-art CP-LRP and traceless polymer-peptide conjugation 
methods enabled the synthesis of well-defined col-PPEGA 
systems and highlighted their potential as prodrug alternatives 
to CMS. Moreover, it was demonstrated that this CP-LRP 
methodology represents a powerful approach for the ‘grafting-
from’ polymer modification of biological entities and opens 
new opportunities for future polymer-peptide conjugation 
strategies. 
EXPERIMENTAL PROCEDURES 
Synthesis of initiator precursor, 2-((2-bromo-2-
methylpropanoyl)oxy)acetic acid (BMPAA) 
Glycolic acid (3.00 g, 40 mmol, 1.0 equiv.) was dissolved with 
DCM (60 mL) and N,N-diisopropylethylamine (DIPEA, 8 mL, 
45 mmol, 1.125 equiv.) in a 250 mL 3-neck round bottom 
flask under N2. The reaction mixture was kept stirring in an ice 
bath for 30 min before the dropwise addition of α-
bromoisobutyryl bromide (6 mL, 50 mmol, 1.25 equiv.) along 
with DCM (30 mL) through a dropping funnel. After the addi-
tion of all the chemicals, the system was gradually warmed up 
to room temperature and left overnight. The solvent was sub-
sequently removed under vacuum and the crude product was 
extracted by diethyl ether/0.2 M hydrochloric acid (HCl) solu-
tion to remove the remaining DIPEA. After the removal of 
solvent, the product was then purified by Kugelrohr Distilla-
tion. The product is normally obtained as a white solid with a 
slight amount of an acid impurity (which we suspected it to be 
α-bromoisobutyric acid) at 50 oC to 100 oC under 2.2x10-2 
mbar. The purity of the product can be analyzed by TLC plate 
(diethyl ether: AcOH = 400: 1 v/v). A further purification can 
be performed by the recrystallization from hot hexane. The 
final product consists of white flaky crystals with a yield of 
3.6 g (16 mmol, 40%). 1H-NMR (300 MHz, CDCl3, 298 K) δ 
(ppm) = 1.99 (-C(CH3)2Br), 4.76 (-OCH2CO-) and 7.83 (br, -
COOH).13C-NMR (75.5 MHz, CDCl3, 298 K) δ (ppm) = 30.73 
(-C(CH3)2Br), 54.56 (-C(CH3)2Br), 61.12 (-OCH2CO-), 171.21 
(-COOCH2CO-), 172.74 (-OCH2CO-).IR (neat) /cm-1: 3300-
2300 (O-H), 2975, 2865 (CH2, CH3), 1724, 1706 (C=O), 1421, 
1248, 1147.HR-MS (ESI, negative mode): m/z (found) 
222.9607 (M-H), m/z (calculated) 222.9611 (M-H). 
Synthesis of Boc5-colistin-Br2 (Boc5-col-Br2) 
The synthesis of Boc5-colistin-Br2 was modified from the 
standard Steglich esterification.  1.00 g of colistin sulphate 
(0.789 mmol, 1 equiv.) was converted into Boc5-colistin based 
on the previous report.22 The crude Boc5-colistin product (~ 
1.10 g) was then dissolved in anhydrous THF (50 mL), follow-
ing the addition of 2-((2-bromo-2-methylpropanoyl)oxy)acetic 
 acid (885.0 mg, 3.95 mmol, 5 equiv.) and DMAP (48.0 mg, 
0.393 mmol, 0.5 equiv.). After the chemicals completely dis-
solved, N,N'-dicyclohexylcarbodiimide (DCC, 977.0 mg, 4.74 
mmol, 6 equiv.) was added afterwards and the reaction mix-
ture was kept stirring overnight. The reaction mixture was then 
centrifuged to remove most of insoluble compounds. The sol-
vent was then removed under vacuum and a further purifica-
tion was performed by the flash column (0% -10% MeOH in 
DCM). The final product is a fine pale yellow powder with a 
total yield of 0.96 g (0.463 mmol, 59%).  
Procedure for the polymerization of MA using colistin ini-
tiator Boc5-colistin-Br2 
The polymerization condition of MA was modified from pre-
vious report.39 A nail gel curing box with four 9 Watt bulbs 
was used as a UV source. MA was passed through a short 
basic aluminium column to remove the inhibitor prior to use. 
A stock solution of CuBr2 (1 mg/mL in DMSO) and the ligand 
Me6TREN (6.5 μL/mL in DMSO) was freshly prepared before 
the reaction. MA (73 μL, 0.80 mmol, 40 equiv., 20 equiv. per 
arm), Boc5-colistin-Br2 (42 mg, 20 μmol, 1 equiv.), CuBr2 
stock solution (90 μL, 0.4 μmol, 0.02 equiv.), Me6TREN stock 
solution (100 μL, 2.4 μmol, 0.12 equiv.) were added to a 2 mL 
vial. 102 μL DMSO was then added to make the mono-
mer/solvent ratio to around 1: 4. The reaction mixture was 
then stirred until all the compounds were dissolved. The sys-
tem was then sealed and carefully degassed by purging with 
N2 for 15 min (make sure the monomer is not blown off by the 
N2). The polymerization was performed under UV with a cool-
ing plate (CAMLAB, KP283) to maintain the reaction temper-
ature. The reaction was stopped at 4h and the conversion were 
measured using 1H-NMR (Figure S1). MALDI-ToF MS and 
GPC analyses were also conducted to evaluate the molecular 
weight and dispersity of the polymer (Figure 2). 
The cleavage of the linker from PMA-Boc5-colistin conjugate 
was conducted directly using the crude polymer obtained from 
previous procedure. 100 μL of the crude polymer was diluted 
by 1 mL 3% NaOMe in MeOH and the reaction mixture was 
kept stirring at ambient temperature for 1 day. The solvent was 
then blown off by N2 and the product were analysis by 
MALDI-ToF MS and GPC (Figure 2). 
Polymerization of PEGA480 of different DPs using colistin 
initiator Boc5-colistin-Br2 
The polymerization procedure of PEGA480 was similar to that 
used for MA. The ratio of [initiator]: [CuBr2]: [ligand] was 
kept the same as the one used in the polymerization of MA (1: 
0.02: 0.12). The PEGA480 monomer to initiator ratio was set to 
10:1, 20:1, 40:1 for the synthesis of DP5, DP10, and DP20 
polymer, respectively. For the synthesis of DP10 and DP20 
polymer, 21 mg colistin initiator was used and the mono-
mer/DMSO ratio was changed to 1: 2 so that the reaction time 
was shorten to 2 h instead of the standard 4h to reach high 
monomer conversion (> 90%) which can be analyzed by 1H-
NMR. To minimise the hydrolysis during the purification 
steps, the further separation of the polymer and the trace 
PEGA480 monomer was done by diluting the crude using ACN 
and purifying by RP-HPLC (0-12 min 50%-100% B; 12-20 
min 100% B, 20-21 min 100%-50% B; 21-30 min 50% B). 
The polymer peak would be found from 8-15 min depending 
on the DP.  Once collected from RP-HPLC, the product was 
frozen by liquid N2 and the solvents were directly removed 
under high vacuum. The products before and after the purifica-
tion were performed by GPC and HPLC analysis to observe 
whether any change was occurred during the purification step. 
Deprotection of Boc groups from Boc5-col-PPEGA conju-
gates 
The cleavage of Boc groups on the colistin initiator from the 
polymer conjugates to regenerate col-PPEG conjugates were 
performed under the similar conditions described previously 
using 20% TFA in DCM.22 Briefly, 5 mL 20 % TFA in DCM 
was added slowly into the purified polymer conjugates. [Be 
cautious of the release of gas!] After most gas was released, 
the reaction mixture was sealed and kept stirring at ambient 
temperature overnight. After the removal of solvents, the 
product was frozen by liquid N2 and all the solvents were di-
rectly removed under high vacuum. The products were per-
formed by GPC and HPLC analysis for comparison. 
Protocol for in vitro releasability of col-PPEGA prodrugs 
The degradation of the col-PPEGA conjugates was based on 
the previous report.22 Each conjugate was weighed into a 2 mL 
vial, followed by the addition of a certain amount of PBS (1X) 
to make the final concentration of 0.4 μmol/mL. 900 µL of 
each prodrug solution was taken into another vial and incubat-
ed in an oil bath with stirring at 37 oC. The rest of each pro-
drug solution (> 500 µL) was stirred at room temperature. 
Samples (85 μL each time) were taken periodically and frozen 
by liquid nitrogen before the analysis. The analysis was con-
ducted by RP-HPLC (injection volume = 70 µL) using the 
standard analysis condition. The colistin release percentage 
was calculated based on the reported method.  
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